Jinan, China

Hong Liu

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Shandong Provincial Institute of Dermatology and V, Shandong University. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hong Liu. Retrieved from https://idiyas.com/inventor/hong-liu-ex1vv2p4

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Inventor Hong Liu

Introduction

Hong Liu is a notable inventor based in Jinan, China. He has made significant contributions to the field of biomedical engineering, particularly in the areas of cell classification and drug reaction evaluation. With a total of 2 patents, Liu's work has the potential to impact medical diagnostics and treatment protocols.

Latest Patents

One of Liu's latest patents is a "Label-free cell classification and screening system based on hybrid transfer learning." This innovative system includes a data preprocessing module that acquires 2D light scattering video data and performs digital cell filtering. The system features a label-free high-content video flow cytometry, which consists of an optical excitation module, a sheath flow control module, and a data acquisition and processing module. Additionally, an image archiving module is utilized to sort and label cells, while a convolutional neural network is employed in the feature extraction module to obtain image data feature vectors. The cell classification and screening module uses a support vector machine model to derive cell screening results.

Another significant patent by Liu involves the "Use of HLA-B*1301 allele." This invention outlines methods for detecting whether a person possesses the HLA-B*1301 allele, which is crucial for evaluating the risk of adverse drug reactions to dapsone. The patent details that individuals with the HLA-B*1301 allele are at a higher risk of experiencing adverse reactions when administered dapsone, particularly those with the allele present on both chromosomes.

Career Highlights

Hong Liu has worked with esteemed institutions such as Shandong University and the Shandong Provincial Institute of Dermatology. His research and innovations have garnered attention in the scientific community, contributing to advancements in medical technology.

Collaborations

Liu has collaborated with notable colleagues, including Xuantao Su and Zhuo Wang, enhancing the scope and impact of his research endeavors.

Conclusion

In summary, Hong Liu's innovative patents and contributions to biomedical engineering demonstrate his commitment to advancing medical diagnostics and treatment. His work continues to pave the way for future developments in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…